Targeted therapy in metastatic renal carcinoma

Cancer Letters

Volumn 343, Issue 2, 2014, Pages 156-160

  Mattei, Jane ^a   da Silva, Rodrigo Donalisio ^a   Sehrt, David ^a   Molina, Wilson R ^a   Kim, Fernando J ^a  

^a DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

Adjuvant treatment; Metastatic disease; Renal cell carcinoma; Renal tumor; Target therapy

Indexed keywords

AXITINIB; BEVACIZUMAB; CEDIRANIB; ERLOTINIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PLACEBO; RAPAMYCIN; RECOMBINANT ALPHA INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CLEAR CELL CARCINOMA; CYTOREDUCTIVE SURGERY; DEHYDRATION; DIARRHEA; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; DYSPNEA; EVIDENCE BASED MEDICINE; FATIGUE; FOOD AND DRUG ADMINISTRATION; HAIR DISEASE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER TOXICITY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NEPHRECTOMY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; SHORT SURVEY; SKIN EXFOLIATION; STOMATITIS; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING;

ADJUVANT TREATMENT; METASTATIC DISEASE; RENAL CELL CARCINOMA; RENAL TUMOR; TARGET THERAPY;

CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASM METASTASIS; REMISSION INDUCTION;

EID: 84891829996     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.09.038     Document Type: Review

References (40)

1. Najjar Y., Rini B. Novel agents in renal carcinoma: a reality check. Ther. Adv. Med. Oncol. 2012, 4(4):183-194.
2. Stadler W. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 2005, 104(11):2323-2333.
3. Berg W., Divgi C., Nanus D., Motzer R. Novel investigative approaches for advanced renal cell carcinoma. Semin. Oncol. 2000, 27(2):234-239.
4. Dorff T., Goldkorn A., Quinn D. Targeted therapy in renal cancer. Ther. Adv. Med. Oncol. 2009, 1(3):183-205.
5. Janusz R., Robert S. Rasregulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol. 2001, 333:267-283.
6. Hilger R., Scheulen M., Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002 December, 25(6):511-518.
7. Sorafenib Rini B. Expert. Opin. Pharmacother. 2006, 7(4):453-461.
8. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl. J. Med. 2007, 356(2):125-134.
9. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24(16):2505-2512.
10. Motzer R., Rini B., Bukowski R., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295(21):2516-2524.
11. Sunitinib Rini B. Expert. Opin. Pharmacother. 2007, 8(14):2359-2369.
12. Motzer R., Hutson T., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl. J. Med. 2007, 356(2):115-124.
13. Cella D., Li J., Cappelleri J., et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J. Clin. Oncol. 2008, 26(22):3763-3769.
14. Vakkalanka B., Bukowski R. Novel drugs for renal cell carcinoma. Expert Opin. Investig. Drugs 2008, 17(10):1501-1516.
15. Al-Marrawi M., Rini B. Pazopanib for the treatment of renal cancer. Expert Opin. Pharmacother. 2011, 12(7):1171-1189.
16. Vasudev N.S., Larkin J.M. Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib. Clin. Med. Insights Oncol. 2011, 5:333-342.
17. Bukowski R. Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma. Front Oncol. 2012, 2:13.
18. Keisner S., Shah S. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011, 71(4):443-454.
19. Sternberg C., Davis I., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 2010 February 20, 28(6):1061-1068. Epub 2010 January 25.
20. Sonpavde G., Hutson T., Rini B. Axitinib for renal cell carcinoma. Expert Opin. Investig. Drugs 2008, 17(5):741-748.
21. Carmichael C., Lau C., Josephson D., Pal S. Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma. Clin. Adv. Hematol. Oncol. 2012, 10(5):307-314.
22. Rixe O., Bukowski R., Michaelson M., et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007, 8(11):975-984.
23. Rini B., Escudier B., Tomczak P., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378(9807):1931-1939.
24. Mulders P., Hawkins R., Nathan P., et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur. J. Cancer 2012, 48(4):527-537.
25. Rini B., Halabi S., Rosenberg J., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 2008, 26(33):5422-5428.
26. Escudier B., Bellmunt J., Négrier S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 2010, 28(13):2144-2150.
27. P Tang, M Tsao, M Moore A review of erlotinib and its clinical use. Expert Opin. February 2006, (7):177-193.
28. Hainsworth J., Sosman J., Spigel D., Edwards D., Baughman C., Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 2005, 23:7889-7896. ( 2005 by American Society of Clinical Oncology).
29. Bukowski R.M., Kabbinavar F.F., Figlin R.A., et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol. 2007, 25:4536-4541. ( 2007 by American Society of Clinical Oncology).
30. Flaig T., Costa L., Gustafson D., et al. Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br. J. Cancer 2010, 103:796-801.
31. Sonpavde G., Choueiri T. Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. Br. J. Cancer 2012, 107(7):1009-1016.
32. Cho D., Atkins M. Future directions in renal cell carcinoma: 2011 and beyond. Hematol. Oncol. Clin. North Am. 2011, 25(4):917-935.
33. Pinto M., Redondo S., Espinosa A., Zamora A., Castelo F., González B. mTOR pathway inhibition in renal cell carcinoma. Urol. Oncol. July-August 2012, 30(4):356-361. (Epub 2010 March 5).
34. Voss M., Molina A., Motzer R. MTOR inhibitors in advanced renal cell carcinoma. Hematol. Oncol. Clin. North Am. 2011, 25(4):835-852.
35. Amato R. Everolimus for the treatment of advanced renal cell carcinoma. Expert Opin. Pharmacother. 2011, 12(7):1143-1155.
36. Spigel D.R., Anthony Greco F., Waterhouse D.M., et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J. Clin. Oncol. May 1 2010, 28(13):2131-2136. (Epub 2010 April 5).
37. Motzer R., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372(9637):449-456.
38. Motzer R., Hudes G., Curti B., McDermott D., Escudier B. Negrier Sea. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J. Clin. Oncol. 2007, 25(25):3958-3964.
39. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl. J. Med. 2007, 356(22):2271-2281.
40. Ljungberg B., Cowan N.C., Hanbury D.C., Hora M., Kuczyk M.A., Merseburger A.S., Patard J.J., Mulders P.F., Sinescu I.C. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 2010, 58(3):398-406.